MedTrace Logo

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 455

Last updated 2026-02-17

No results posted yet for this study

Summary

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Conditions

  • Refractory or Unexplained Chronic Cough

Interventions

DRUG

NOC-110

Inhalation powder

OTHER

Placebo

Inhalation powder

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Nocion Therapeutics

    lead INDUSTRY

Principal Investigators

  • Matthew Frankel, MD · Chief Medical Officer Nocion Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-24
Primary Completion
2026-04-10
Completion
2026-04-10
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Germany
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06504446 on ClinicalTrials.gov